B2BROKER
20.10.2020 11:02:05 CEST | Business Wire | Press release
B2Broker , a leading liquidity and technology provider of solutions to the forex and crypto industry, is pleased to announce it has launched its new website and new corporate branding. This is the company’s first major website and corporate identity update and is aligned with its expansion plans to position itself as the leading global provider in its genre, having secured over 200 institutional customers to date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020005105/en/
Rationale
While the last few months have presented a challenging situation regarding the Covid-19 global pandemic, B2Broker noted the increases in online trading which impacted on demand for Forex and crypto-related services from brokerages. The situation served as an important trigger to move forward with the new website and branding project to provide current and potential clients access to encyclopedic information and a new experience that is an industry first.
The rationale is summed up by B2Broker Chief Operating Officer, Evgeniya Mykulyak. “We created the previous version of our website two years ago and a lot has since changed…over the course of a year, 15 team members set out to build the best website in the industry, which would not only reflect the full essence of our products, but also provide general information about the industry. Our new logo meanwhile, reflects new values and meanings that are really close to the heart of our company, our team and our products.”
New Branding
The new brand strategy involves the use of 9 circles representing the 9 product groups with the circles depicting the products being perfectly formed like circles, allowing clients to build their business like a jigsaw using the company’s products. The square surrounding the image reflects the security and stability of the company’s products, whilst the colour green represents profitability and margin and the shades - market growth and vitality.
Rollout
The new B2Broker website which has been released in 8 languages officially launched on 14th October, 2020 with clients now being referred to the new domain www.b2broker.com
Arthur Azizov, CEO B2Broker, added, “B2Broker is now in its 6th year of successful operations and our new website and branding is an important milestone in the company’s growth and development. Our newly introduced branding reflects our prime position in the industry, the breadth of technology and liquidity services we offer and the global nature of our operations. This is an exciting company with even bigger plans for the market, and now we have a state-of-the-art website and more distinctive brand that fully expresses our purpose.
About B2Broker
B2Broker’s range of products and services include: Cryptocurrency Liquidity , Forex Liquidity , CFD Liquidity , Forex Broker Turnkey , Crypto Broker Turnkey , Crypto Payment Gateway , B2Core (Trader’s Room and Back Office Software), Investment Platform , MT4 / MT5 White Label solutions , Cryptocurrency Exchange Development and www.b2bx.exchange , all of which contribute to the company’s growing presence across the globe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005105/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom